Gleevec inhibits beta-amyloid production but not Notch cleavage - Test2 - elhamkhani - TriplyDB

Gleevec inhibits beta-amyloid production but not Notch cleavage

Gleevec inhibits beta-amyloid production but not Notch cleavage

http://www.wikidata.org/entity/Q24683037

about

Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes Dynamin 1 regulates amyloid generation through modulation of BACE-1 Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress Selective amyloid-beta lowering agents.Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors.Targeting Abeta and tau in Alzheimer's disease, an early interim report Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).The secretases: enzymes with therapeutic potential in Alzheimer disease.Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment gamma-secretase activating protein is a therapeutic target for alzheimer 's disease: a path-breaking discovery finally paving way towards therapeutic intervention.Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus.Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Target deconvolution techniques in modern phenotypic profiling.Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line 5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo.Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site.Role of zinc metallothionein-3 (ZnMt3) in epidermal growth factor (EGF)-induced c-Abl protein activation and actin polymerization in cultured astrocytes.Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease.Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease Identifying drug-pathway association pairs based on L1L2,1-integrative penalized matrix decomposition.Emerging therapeutics for Alzheimer's disease.The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.Modulators and inhibitors of gamma- and beta-secretases.100 years and counting: prospects for defeating Alzheimer's disease Novel therapeutic strategies for the treatment of protein-misfolding diseases.Gamma-secretase inhibition and modulation for Alzheimer's disease.Intramembrane proteolysis

P2860

Q24298408-799FDC6F-F58B-49E2-8B8D-22A4117E4A9F Q24318974-6FA75CE2-9391-4DCF-9F45-EFE6F1DE6520 Q24676480-2768113B-CEEF-4FAE-8287-74993BD7DD01 Q27315066-B9310838-91E7-49EB-8A68-79A2DBEE5274 Q27318742-D56FC9B1-8817-4FBC-9808-F134CF687726 Q28476697-915BC67D-7356-4056-BD83-B24E18A67A9B Q28537637-08F70576-08CB-4A4D-AD56-31E7B743F00C Q28577875-55DE9E9E-CBC3-483A-A20F-EABAF91FF8DB Q28742427-3CAFEF87-8EF0-45AE-93FB-E8699B64578E Q30419992-BF75E544-22B9-4DBD-AD89-F38D0950B967 Q30855103-4A19DABD-8422-4E3E-9D19-0EE062BEC818 Q33515793-31AEAD3F-D782-4A85-9C41-7A80C44B584A Q33543978-F1343A4F-9C1C-4E6D-8618-DBB252DEA26A Q33829008-54A95ABD-FDE5-4816-9022-88562911E222 Q33836021-AAAA7807-00FB-466E-86DB-406214CCA6F5 Q33887222-DFAAEC7F-322F-423F-B557-E23516B3A1CA Q33894316-0758E4D8-6FB8-4B43-924A-5F998BE65613 Q33979489-3DFBBEA9-5E35-445D-858E-C446DC1A9925 Q34382868-E7813697-DD40-41ED-81F9-387A14204F00 Q34392064-824A0DD9-5B4B-4583-829E-AC3FD8C9826B Q34441015-84CDEA2C-F71C-42EC-BF68-2C6D7B6B7E8E Q34477111-2EF2B317-239C-406F-8AD2-8BE23D83249D Q34543713-A9C865AB-1BEB-466F-85AD-22EAE639ACF1 Q34556513-D7023E25-7722-44D9-BA56-797FC9D3A830 Q34586941-8F488F6F-599D-4E44-B1A6-C681F53735C3 Q34636148-4075F285-49E7-49F3-8017-8B8F55B09855 Q34636863-28C5E3F4-74EB-4AB0-98CD-AE4BC7DB5F7E Q34872108-14AE9FD0-C361-4802-A7B4-4ABDD9EB87D3 Q35562577-302A5139-3955-40AC-9669-EE1102B5854A Q35658184-638FF818-3BD6-4469-AF8B-88ACEAF7639A Q35745694-4DF22C7C-1C68-4058-9D9F-321EE1FC8895 Q36081889-60B0BFD0-8A6F-4538-8E6A-9DDFD5AA3C27 Q36408203-C19152EB-A2F9-4B47-8911-5A646230671E Q36492347-5D071409-2747-493B-A657-9616FCA115E7 Q36562023-1BCF7811-6490-4AC7-8391-EB8ECDD99A35 Q36626443-EEFDFDD2-0970-4934-B283-A4D12C06A603 Q36643419-DBABC8B5-7873-449D-A848-399619146751 Q36863389-7B32CA9B-F735-48BC-BF52-EDC351BD1F28 Q37130650-7ED708CA-798D-4D6F-8728-6311494565A1 Q37155734-5756BDCC-E501-4589-8AAF-509F22BFE834

P2860

Gleevec inhibits beta-amyloid production but not Notch cleavage

http://www.wikidata.org/entity/Q24683037

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Gleevec inhibits beta-amyloid production but not Notch cleavage

@ast

Gleevec inhibits beta-amyloid production but not Notch cleavage

@en

Gleevec inhibits beta-amyloid production but not Notch cleavage

@nl

type

label

Gleevec inhibits beta-amyloid production but not Notch cleavage

@ast

Gleevec inhibits beta-amyloid production but not Notch cleavage

@en

Gleevec inhibits beta-amyloid production but not Notch cleavage

@nl

prefLabel

Gleevec inhibits beta-amyloid production but not Notch cleavage

@ast

Gleevec inhibits beta-amyloid production but not Notch cleavage

@en

Gleevec inhibits beta-amyloid production but not Notch cleavage

@nl

P1433

Q24683037-A8D062A0-6227-4632-A42F-DF3F32059E92

P1476

Q24683037-C1F263E9-7CC4-4EF8-A943-C3984B9287A3

P2093

Q24683037-13292674-F6AD-4D88-BA11-69EFC7081B35

Q24683037-1A5F6B98-0297-4FDE-A4C4-795318C2431D

Q24683037-2BE4E7CA-2A56-4590-B537-9ABF9E4BB8EA

Q24683037-37B00C66-DB5B-4913-8AE9-A8499D9B188E

Q24683037-5A82D68C-83E0-45E3-9735-753EBB045998

Q24683037-648F4C47-6B5A-4869-A525-2DF8D46339C6

Q24683037-679D7831-ABC3-41F0-96F9-043DA9311109

Q24683037-B552FF7F-9BE6-4666-995E-230D5C7B1862

Q24683037-D5AB3B17-5990-4C00-A735-9007A622E11D

P2860

Q24683037-026DF6C5-AC7B-411A-AB72-611E0F3EEB45

Q24683037-091BA793-6134-4CFE-86B4-F14D87E903D2

Q24683037-12B44929-3E42-4715-A40D-C52CAB00E87F

Q24683037-12F98F6E-CE39-40D0-BC57-258354C76ECF

Q24683037-152ED13C-8132-4A37-9495-0D6DDAAF952D

Q24683037-261B8B35-AD7A-420C-A8C0-0D0DD30C364C

Q24683037-2F6F158E-E3DC-47F4-9C6B-6B255693E11B

Q24683037-31D42762-20F8-4B1C-BA20-A75407290FB9

Q24683037-36C4C32E-5BC5-4CF8-A4D2-0EA4BA57A9B6

Q24683037-39F7806F-3EB5-4CAD-9FE8-A743FDB5944C

P304

Q24683037-B5319D07-8920-4B30-AAEC-D0B5DCDD675E

P31

Q24683037-6D876A9F-4A5C-442F-8EAE-1C9B0B16A95C

P356

Q24683037-53070F86-4106-4ACA-983B-7FDEF0FB7A41

P407

Q24683037-56EB6C63-8ADA-4759-B015-942AAD370B31

P433

Q24683037-F5CB0901-8D16-4101-861D-B4E094BF8CC8

P478

Q24683037-F2FF1C0D-0427-4B33-9547-60642DC2492E

P50

Q24683037-24FE3CA0-CB29-4487-9EB1-3BA9B107A168

P577

Q24683037-5ADC241D-878A-44FE-9BCD-DF270EC8229E

P5875

Q24683037-C698BE94-4BB0-4963-89AC-8ABE9BDFE80F

P698

Q24683037-98F4DBDF-A02E-4965-B1E5-E9474494E0A0

P932

Q24683037-7EE45D12-2D2C-4CE8-B91F-9D46E3868EF7

P356

PNAS.1534745100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Gleevec inhibits beta-amyloid production but not Notch cleavage

@en

P2093

Bayard Clarkson

http://www.w3.org/2001/XMLSchema#string

Darren Veach

http://www.w3.org/2001/XMLSchema#string

Dongming Cai

http://www.w3.org/2001/XMLSchema#string

Fei Dou

http://www.w3.org/2001/XMLSchema#string

Huaxi Xu

http://www.w3.org/2001/XMLSchema#string

Stephanie Jean

http://www.w3.org/2001/XMLSchema#string

William G Bornmann

http://www.w3.org/2001/XMLSchema#string

William J Netzer

http://www.w3.org/2001/XMLSchema#string

Yueming Li

http://www.w3.org/2001/XMLSchema#string

P2860

Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

Structural basis for the autoinhibition of c-Abl tyrosine kinase

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency

APP processing and synaptic plasticity in presenilin-1 conditional knockout mice

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

P304

12444-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1534745100

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9069030

http://www.w3.org/2001/XMLSchema#string

P698

14523244

http://www.w3.org/2001/XMLSchema#string

P932

218777

http://www.w3.org/2001/XMLSchema#string